2026-01-01 - Analysis Report
Okay, here's a breakdown and analysis of Tempus AI (TEM) based on the provided data, following your instructions:

**0) Report Summary:**

*   **Return Performance:** TEM is significantly underperforming the S&P 500 (VOO).
*   **Volatility:** High volatility as indicated by the large MDD.
*   **Recent Price Action:** Downtrend, with the price below all Simple Moving Averages.
*   **Technical Indicators:** Oversold (RSI), negative PPO, suggesting a potential rebound.
*   **Market Sentiment:** Mixed, with recent news headlines highlighting both positive growth potential and concerns about the company's pivotal transition. Analyst consensus is leaning towards "Buy" with a significant upside target price.

**1) Return Rate Comparison:**

*   **Company Overview:** Tempus AI Inc. is a technology company applying AI to precision medicine, focusing on data-driven approaches to cancer treatment.
*   **TEM Cumulative Return:** 7.80%
*   **VOO (S&P 500) Cumulative Return:** 31.44%
*   **Divergence:** -23.6 (Relative Divergence: 14.8).  This means TEM has significantly underperformed the S&P 500, and its relative divergence is at 14.8/100 within the defined band, indicating that the divergence relative to historical data is at the low end of the spectrum.

**Analysis of Alpha, Beta, CAGR, MDD, Cap:**

*   **Year:** 2024-2026 (estimated)
*   **CAGR (Compound Annual Growth Rate):** 8.0%.  Indicates an expected average annual growth of 8%.
*   **MDD (Maximum Drawdown):** 76.7%. A very high MDD indicates significant potential for large losses from peak to trough.
*   **Alpha:** -23.0%. TEM is underperforming relative to its benchmark.
*   **Beta:** 0.3. Lower than 1 suggests TEM is less volatile than the market.
*   **Cap(B) (Market Cap in Billions):** 10.6 B
    

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 60.39
*   **Last Market Price:** 59.54 (Previous Close: 60.39, Change: -1.41) The price has dipped slightly from the previous close.
*   **5-day SMA:** 62.71
*   **20-day SMA:** 69.16
*   **60-day SMA:** 77.99

**Analysis:** The stock is trading below all its SMAs, indicating a current downtrend.  The short-term SMA is lower than the longer-term SMAs, reinforcing this downward momentum.

**3) Analysis of RSI, PPO, MRI, Hybrid Signal, and Expected Return:**

*   **MRI (Market Risk Indicator):** 0.9 (Medium Investment). Suggests a moderate level of risk.
*   **RSI (Relative Strength Index):** 16.19.  This is significantly oversold territory (below 30).  It often suggests a potential bounce back or reversal.
*   **PPO (Percentage Price Oscillator):** -1.03.  Negative PPO reinforces the downtrend.
*   **Hybrid Signal:** "cash\_0% Buy 100% of cash (14 shares - Very Safe - MRI:0.90) Monthly invest 5.0% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)".  The system recommends buying with all available cash, based on its model.
*   **Recent (20 days) relative divergence change:** -9.1 (-): Indicates a short-term downtrend.
*   **Change in Last Market Price:** {'price': 59.54, 'previousClose': 60.39, 'change': -1.41} fluctuation issue (sharp rebound, sharp decline).
*   **Expected Return (%):** NaN.  No expected return data is available.

**Analysis:**  The very low RSI suggests the stock may be oversold and could experience a short-term rebound. The MRI indicates medium risk.

**4) Recent News & Significant Events:**

*   **Positive AI Boom Potential (Nasdaq):**  The article mentions Tempus AI as one of the MedTech stocks that could benefit from the AI boom in 2026. This points to future growth potential.
*   **Institutional Buying (MarketBeat):** Renaissance Capital LLC bought 17,866 shares, indicating some institutional confidence.
*   **Pivotal Transition (Yahoo Finance):**  The article raises questions about whether TEM is a buy, hold, or sell during its transition. This suggests uncertainty.
*   **FDA Clearance & Price Drop (Quiver Quantitative):** Mentions opinions on FDA clearance and a price drop, indicating sensitivity to regulatory news and potential volatility.
*   **TEM vs. HIMS Comparison (Finviz):**  Compares TEM to a competitor, which can be useful for understanding relative value.
*   **2025 Performance (TIKR.com):** Highlights significant positive performance in 2025, suggesting it has had positive runs in the past.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.14)
*   **Target Price (Avg/High/Low):** 88.92 / 105.00 / 80.00

**Analysis:** The analyst consensus and target prices suggest significant upside potential from the current price.

**5) Comprehensive Analysis:**

Tempus AI presents a mixed picture. While it has underperformed the S&P 500 significantly and exhibits high volatility (high MDD), several factors suggest potential for future growth and a possible short-term rebound:

*   **Oversold Condition:** The very low RSI indicates the stock might be oversold.
*   **Analyst Sentiment:** The "Buy" consensus and high target prices suggest analysts see considerable upside.
*   **AI Boom Potential:** News articles highlight the potential for Tempus AI to benefit from the increasing use of AI in healthcare.
*   **Institutional Buying:** Recent purchases by Renaissance Capital indicate some confidence from institutional investors.

**However, significant risks remain:**

*   **Underperformance:**  The large divergence from the S&P 500 raises concerns about the company's overall performance.
*   **Pivotal Transition:** The Yahoo Finance article points to uncertainty surrounding the company's transition.
*   **Volatility:** The high MDD means this stock is not for risk-averse investors.
*   **Negative Recent Trend:** Trading below all moving averages and negative divergence change reflect recent negative market sentiment.

**In conclusion:** Tempus AI appears to be a high-risk, high-reward investment. The potential for growth in the AI-driven healthcare sector, combined with positive analyst sentiment, suggests upside potential. However, the stock's underperformance, volatility, and the uncertainty surrounding its current transition warrant caution. Investors should carefully consider their risk tolerance and conduct further due diligence before investing.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.